Safety of selective IL‐23p19 inhibitors for the treatment of psoriasis

por Crowley, J.J., Warren, R.B., Cather, J.C.
Publicado 2019

Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH

por Poulin, Y, Crowley, JJ, Langley, RG, Unnebrink, K, Goldblum, OM, Valdecantos, WC
Publicado 2014

Baseline patient‐reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice

por Kimball, A.B., Crowley, J.J., Papp, K., Calimlim, B., Duan, Y., Fleischer, A.B., Sobell, J.
Publicado 2020

Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities

por Crowley, JJ, Mekkes, JR, Zouboulis, CC, Scheinfeld, N, Kimball, A, Sundaram, M, Gu, Y, Okun, MM, Kerdel, F
Publicado 2014

Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase‐3, randomized, placebo‐controlled trial

por Elewski, B.E., Baker, C.S., Crowley, J.J., Poulin, Y., Okun, M.M., Calimlim, B., Geng, Z., Reyes Servin, O., Rich, P.A.
Publicado 2019

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded t...

por Blauvelt, A., Leonardi, C., Elewski, B., Crowley, J.J., Guenther, L.C., Gooderham, M., Langley, R.G., Vender, R., Pinter, A., Griffiths, C.E.M., Tada, Y., Elmaraghy, H., Lima, R.G., Gallo, G., Renda, L., Burge, R., Park, S.Y., Zhu, B., Papp, K.
Publicado 2020